NYSE:PBH • US74112D1019
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRESTIGE CONSUMER HEALTHCARE (PBH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | Jefferies | Maintains | Hold -> Hold |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-27 | Jefferies | Maintains | Hold -> Hold |
| 2025-10-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-21 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-02-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-02-07 | DA Davidson | Maintains | Buy -> Buy |
| 2025-02-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-11 | DA Davidson | Maintains | Buy -> Buy |
| 2024-08-28 | DA Davidson | Maintains | Buy -> Buy |
| 2024-08-09 | DA Davidson | Maintains | Buy -> Buy |
| 2024-06-21 | DA Davidson | Upgrade | Neutral -> Buy |
| 2024-05-21 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-16 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-06-26 | DA Davidson | Reiterate | Neutral -> Neutral |
| 2023-05-08 | DA Davidson | Reiterate | Neutral |
| 2023-03-17 | RBC Capital | Maintains | Sector Perform |
| 2023-02-17 | Oppenheimer | Maintains | Outperform |
| 2023-01-13 | Oppenheimer | Maintains | Outperform |
| 2022-11-17 | Canaccord Genuity | Initiate | Buy |
| 2022-05-10 | Jefferies | Upgrade | Hold -> Buy |
| 2022-05-09 | DA Davidson | Maintains | Neutral |
| 2022-05-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-03-11 | BMO Capital | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.128B 3.76% | 1.125B -0.21% | 1.138B 1.10% | 1.113B -2.18% | 1.161B 4.31% | 1.241B 6.89% | 1.164B -6.20% | 1.183B 1.63% | 1.181B -0.17% | |
| EBITDA YoY % growth | 385.527M 6.50% | 373.104M -3.22% | 379.414M 1.69% | 364.86M -3.84% | 383.52M 5.11% | 406.7M 6.04% | 389.42M -4.25% | 398.64M 2.37% | 397.94M -0.18% | |
| EBIT YoY % growth | 352.902M 6.97% | 342.429M -2.97% | 349.241M 1.99% | 335.8M -3.85% | 344.62M 2.63% | 353.84M 2.68% | 357.9M 1.15% | 367.21M 2.60% | 368.65M 0.39% | |
| Operating Margin | 31.29% | 30.43% | 30.70% | 30.17% | 29.68% | 28.51% | 30.75% | 31.04% | 31.22% | |
| EPS YoY % growth | -1.68 -141.38% | 4.17 348.21% | 4.53 8.63% | 4.59 1.22% | 4.86 5.89% | 5.16 6.17% | 5.29 2.57% | 5.59 5.64% | 5.53 -0.90% |
All data in USD
| Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.40 6.36% | 1.01 5.95% | 1.16 8.36% | 1.23 7.91% | 1.46 4.17% | 1.08 7.77% | 1.26 8.41% | 1.33 8.37% | 1.57 7.67% |
| Revenue Q2Q % growth | 297.67M 0.39% | 258.06M 3.42% | 283.82M 3.54% | 313.1M 10.46% | 322.04M 8.19% | 304.85M 18.13% | 332.44M 17.13% | 346.91M 10.80% | 356.84M 10.81% |
| EBITDA Q2Q % growth | 106.97M -18.39% | 82.045M 3.30% | 91.58M -3.60% | 100.89M -4.29% | 116.1M 8.54% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 99.234M -1.65% | 74.281M 3.52% | 83.647M 4.99% | 91.468M 10.88% | 105.48M 6.29% | N/A | N/A | N/A | N/A |
All data in USD
10 analysts have analysed PBH and the average price target is 79.76 USD. This implies a price increase of 39.81% is expected in the next year compared to the current price of 57.05.
PRESTIGE CONSUMER HEALTHCARE (PBH) will report earnings on 2026-04-30, before the market open.
The consensus EPS estimate for the next earnings of PRESTIGE CONSUMER HEALTHCARE (PBH) is 1.4 USD and the consensus revenue estimate is 297.67M USD.
The consensus rating for PRESTIGE CONSUMER HEALTHCARE (PBH) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.